title: Oncoepigenomics: making histone lysine methylation count.
abstract: Increasing studies show that methylation of histone lysine residues is implicated in the development and progression of varying disease states such as schizophrenia, diabetes, and multiple human cancers. Targeting the specific enzymes responsible for these processes has fueled global investigation into the understanding and correction of epigenetic pathology. This review aims to assemble a timely account of the current progress against chromatin-modifying histone lysine methyltransferases (KMTs) and demethylases (KDMs) to inform ongoing and future efforts into this promising field. In particular, we report on their role in tumor growth and progression and the development of small molecules that modulate these enzymes.
authors.affiliation: Department of Pharmaceutical Sciences, University of Connecticut, 69 N Eagleville Rd., Unit 3092, Storrs, CT 06269-3092, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Decarlo
authors.forename: M Kyle
authors.initials: MK
authors.lastname: Hadden
mesh_terms: D000818:Animals; D057890:Epigenomics; D056466:Histone Demethylases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011495:Histone-Lysine N-Methyltransferase / Q000037:antagonists & inhibitors / Q000378:metabolism; D006657:Histones / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008239:Lysine / Q000235:genetics / Q000378:metabolism*; D008745:Methylation; D009369:Neoplasms / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology
chemical_list: D006657:Histones; D056466:Histone Demethylases; D011495:Histone-Lysine N-Methyltransferase; D008239:Lysine